Merck and Bristol-Myers Squibb go head to head in cancer market

Bristol-Myers Squibb (BMS) and Merck are set to continue their strong rivalry in the head and neck cancer space, according to GlobalData

The research and consulting company has said that both Merck and Bristol-Myers Squibb are currently racing their PD-1 inhibitory monoclonal antibodies, Opdivo and Keytruda, into the market.

Both drugs have shown promise in clinical trials and could do very well in the head and neck cancer market which, as stated in GlobalData’s most recent Head and Neck Cancer report, will grow rapidly to more than £1.02bn ($1.5bn) by 2024.

Amy Yip, GlobalData's analyst covering oncology and hematology, said: “Recent trials evaluating Opdivo’s efficacy in recurrent or metastatic head and neck squamous cell carcinoma, found that it resulted in a 30% reduction in the risk of death, and a significant improvement compared to the only targeted agent currently approved for the disease, Eli Lilly’s Erbitux (cetuximab).

“Keytruda, on the other hand, in a single-arm Phase Ib trial, was found to produce an overall response rate of 24.8%, including a complete response in one patient.

“This compares favourably with the 10-15% response rate commonly reported for Erbitux monotherapy. In this way, as both Opdivo and Keytruda have shown significant superiority over current standard treatments, their success could depend on how soon they are approved by the FDA.”

GlobalData has said that as the first to file, Keytruda could become the first checkpoint inhibitor to reach the market. However, a filing for Opdivo is expected to occur soon and is likely to gain full FDA approval on the strength of BMS’ Phase III data. Opdivo’s recently-awarded breakthrough therapy designation for head and neck cancers should also expedite the FDA approval process.

If both agents gain a second-line approval, it will be difficult to predict which of the two will garner the larger market share, and the implications for BMS and Merck could vary widely, according to GlobalData.

Yip explains: “Even in a decidedly niche indication such as head and neck cancer, there is a potential difference of hundreds of millions of dollars in sales at stake across therapy lines between the first-to-market product and the runner-up.

“GlobalData believes that the pressure on both companies is only going to rise while the race between BMS and Merck comes to a close.”